
Valitse etikettisi
näkyy suoraan injektiopullossaReta + Tesamorelin Blend
GLP-1
- Lähetetään Saksasta
Tilaus
- DHL seurannalla
- Huomaamaton pakkaus
Yhdellä silmäyksellä
Reta + Tesamorelin Blend lukuina
Tietopankkimme keskeiset luvut.
Koko tietopankkiartikkeli- Type
- Injectable blendtriple agonist + GHRH analog
- Sizes
- 20 mg1 size in the shop
What studies show
All 4 sources in the lexiconRetatrutide phase 2 trial (obesity), 48 weeks, NEJM 2023 (opens in a new tab)
New England Journal of Medicine (PubMed PMID 37366315)Retatrutide systematic review + meta-analysis (878 patients), 2025 (opens in a new tab)
Proc (Bayl Univ Med Cent) (PubMed PMID 40291085)Tesamorelin phase 3 trial (visceral fat, HIV), 12 months (opens in a new tab)
J Acquir Immune Defic Syndr (PubMed PMID 20101189)
Arvostelut
Mitä asiakkaat sanovat
Vain todelliset tilaukset, joissa oli Reta + Tesamorelin Blend.
Kaikki arvostelutTuotteelle Reta + Tesamorelin Blend ei ole vielä laboratorioanalyysia. Äänestä sitäTestauta itse, me maksamme puoletKaikki laboratorioanalyysit
Tietoa
Kaikki aiheesta Reta + Tesamorelin Blend
Tarkemmat tiedot tulossa pian.
Annostelu
Ladataan annostelutietoja …
Tilaa samalla
Mitä tarvitset sen kanssa
Bakteriostaattinen vesi lisätään ostoskoriisi automaattisesti. Ruiskut ja pyyhkeet yhdellä napsautuksella.
Insuliiniruiskut
10 kpl · 5.50 €
Alkoholipyyhkeet
50 kpl · 10 €
Kuinka paljon vettä?
Ruiskun yksiköt injektiopullosi koolle.
Avaa laskuri →Is the Reta + Tesamorelin Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and tesamorelin together. Tesamorelin alone has been approved in the USA since 2010, Retatrutide is in phase 3 and not approved.
What is the catch with the fixed mix?
The two substances were studied on very different schedules: Retatrutide once a week, tesamorelin daily. In a 1:1 vial the ranges from both trial programmes cannot be matched at the same time. The entry therefore goes by the Retatrutide share.
What do the Retatrutide trials show?
In phase 2 body weight fell by 24.2 percent after 48 weeks at the highest study dose, by 2.1 percent on placebo. In phase 3 (TRIUMPH-1) it was 25.0 versus 3.9 percent after 80 weeks. A meta-analysis with 878 participants confirmed clear effects on weight and metabolic values.
What do the tesamorelin trials show?
In 806 patients with HIV and excess belly fat, visceral fat fell by 15.4 percent more than on placebo in 26 weeks, subcutaneous fat stayed nearly the same. IGF-1 rose, blood sugar stayed stable. Those who continued kept the effect to week 52.
Which side effects were seen with the components?
Retatrutide: mainly nausea, diarrhoea and other gastrointestinal effects, depending on the dose, plus a slight rise in heart rate. Tesamorelin: injection site reactions, joint and muscle pain, fluid retention and tingling. There is no safety profile for the blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The phase 3 trials of tesamorelin were completed years ago. No trial of the blend is listed in the registry.
Liittyvät
Samankaltaiset tuotteet
Tirzepatide
Peptidit · GLP-1 ja rasvanpoltto GLP-1 ja rasvanpoltto
10 kokoa
Laboratoriotestattu
= alkaen 10 €/injektiopullo
Retatrutide
Peptidit · GLP-1 ja rasvanpoltto GLP-1 ja rasvanpoltto
11 kokoa
Laboratoriotestattu
= alkaen 16 €/injektiopullo
Semaglutide
Peptidit · GLP-1 ja rasvanpoltto GLP-1 ja rasvanpoltto
6 kokoa
Laboratoriotestattu
= alkaen 10 €/injektiopullo
Mazdutide
Peptidit · GLP-1 ja rasvanpoltto GLP-1 ja rasvanpoltto
2 kokoa
= alkaen 32 €/injektiopullo
Reta + Tesamorelin Blend